Bristol-Myers Squibb (BMY)

$39.66 0.00 (0.00%)

19:00 EDT BMY Stock Quote Delayed 30 Minutes

5 Top Stock Trades for Tuesday: AAPL, GM, SRPT

By Bret Kenwell, InvestorPlace Contributor Oct 7, 2019

Apple, General Motors, Delta Air Lines, Sarepta and Bristol-Myers Squibb were our top stock trades to watch for Tuesday. Here's what you need to know.

7 of the Best Stocks to Buy for Growth Investors

3 Cancer-Fighting Drug Stocks to Buy Right Now

4 Healthcare Stocks to Buy Now

Volume:

Previous Close -

Market Cap 88.13B

PE Ratio -12.79

EPS -3.1

Volume (Avg. Vol.) 144

Day's Range -

52-Week Range $39.35 - $65.38

Dividend & Yield $2.28 (5.75%)

BMY Stock Predictions, Articles, and Bristol-Myers Squibb News

4 Top Stock Trades for Tuesday: AAPL, DIS, BMY

By Bret Kenwell, InvestorPlace Contributor Sep 30, 2019

Apple, Disney, Thor Industries and Bristol-Myers Squibb were our top stock trades from Monday. Here's a look at the charts.

7 Big Biotech Stocks to Watch

By Chris Lau, InvestorPlace Contributor Sep 27, 2019

Biotech stocks are still out of favor because of macro uncertainties. But beneath that, investors may find companies trading at deep value.

10 Cheap Stocks to Buy at Less Than 10x Forward Earnings

By Vince Martin, InvestorPlace Contributor Sep 27, 2019

Low P/E stocks often are cheap stocks for a reason. But these 10 stocks to buy have not just reasonable valuations, but strong bull cases.

4 Top Stock Trades for Thursday: ROKU, ADBE, BYND

By Bret Kenwell, InvestorPlace Contributor Sep 18, 2019

Roku, Adobe Systems, Beyond Meat and Bristol-Myers Squibb are our top stock trades. Read on to see what the charts say.

10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond

By Vince Martin, InvestorPlace Contributor Aug 28, 2019

These 10 stocks don't quite qualify as "set it and forget it" plays. All have some degree of risk. But the risks seem worth taking for the potential rewards, which include near-term income, longer-term growth, and potential capital appreciation.

4 Biotech Stocks to Buy That Are on the Move

By William Roth, InvestorPlace Market Strategist Aug 27, 2019

Biotech stocks overall are holding up fairly well amid recent market volatility. Look at which four biotech stocks to buy have staying power.

Amgen to Buy Celgene’s Otezla for $13.4B: Is the Deal Good for Amgen Stock?

By Aug 27, 2019

Amgen's purchase of Celgenes blockbuster psoriasis drug, Otezla is likely to strengthen its position in the immunology space and boost Amgen stock.

Stock Market Today: Biotech in Focus, Trade Talks Steady Stocks

By Bret Kenwell, InvestorPlace Contributor Aug 26, 2019

Trade talks gave a lift to stocks, while Johnson & Johnson will be in focus after the close. Here's what happened in the stock market today.

5 Top Stock Trades for Tuesday: NFLX, AMGN, ACB, BMY

By Bret Kenwell, InvestorPlace Contributor Aug 26, 2019

Netflix, Amgen, Bristol-Myers Squibb, Aurora Cannabis and Foot Locker are our top stock trades for Tuesday. Here's how to trade them.

Celgene News: CELG Stock Jumps on Sale of Otezla to Amgen

By William White, InvestorPlace Writer Aug 26, 2019

Celgene news for Thursday about it selling Otezla has CELG stock on the rise as it moves forward with the Bristol-Myers Squibb merger.

5 Healthcare Stocks to Buy for Healthy Dividends

By Aaron Levitt, InvestorPlace Contributor Aug 23, 2019

Healthcare stocks are among the best growth and income plays. Here are five firms in the sector that have the goods to keep growing and paying strong dividends.

8 Biotech Stocks to Watch After the Q2 Earnings Season

By Chris Lau, InvestorPlace Contributor Aug 20, 2019

Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.

Bristol-Myers Squibb Stock Has Upside — But Mind the Risks

By Vince Martin, InvestorPlace Contributor Aug 12, 2019

Bristol-Myers Squibb stock touched a multi-year low last month. But the BMY stock price is cheap enough now to take on real risks.

Risk-Takers Have a Reasonable Shot with BMY Stock

By Josh Enomoto, InvestorPlace Contributor Aug 9, 2019

Political pressures regarding drug pricing and Bristol-Myers’ disappointing clinical trails have contributed to a disappointing performance for BMY stock. Still, much of this bearishness could be priced in already.